Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company reported a revenue of 1.736 billion yuan in Q3 2025, a year-on-year decrease of 11.6%, with a net profit of 227 million yuan, down 23.6%. For the first three quarters, the total revenue was 7.098 billion yuan, an increase of 1.9%, and the net profit was 1.026 billion yuan, up 2.7% [9] - The company is focusing on enhancing profitability through cost reduction and efficiency improvements, with a gross margin of 74.7% in Q3 2025, an increase of 4.0 percentage points [9] - The company has signed a strategic cooperation agreement with West China Hospital to focus on mitochondrial anti-aging research, and its sub-brands OR and Yuanse Bota are showing strong growth [9] - The company is expected to achieve net profits of 1.615 billion yuan, 1.818 billion yuan, and 2.038 billion yuan for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 17.9, 15.9, and 14.2 [9] Financial Performance - The company's revenue for 2023 is projected at 8.905 billion yuan, with a growth rate of 39.5%. For 2024, revenue is expected to reach 10.778 billion yuan, with a growth rate of 21.0% [8] - The net profit for 2023 is estimated at 1.194 billion yuan, with a growth rate of 46.1%, and for 2024, it is projected to be 1.552 billion yuan, with a growth rate of 30.0% [8] - The company's EPS for 2025 is expected to be 4.08 yuan, with a PE ratio of 17.9 [8] Market Performance - The company's stock has shown a performance of -22% over the last 12 months compared to the CSI 300 index [4]

Core Viewpoint - The article highlights the success of Ziyuan's Sapindus Mukorossi (Soapberry) series, which has sold 150 million bottles globally, showcasing the integration of Eastern botanical wisdom with modern scientific validation in the hair care industry [1][24][29] Group 1: Research and Development Achievements - Ziyuan's research on the fermentation essence of Sapindus Mukorossi has been published in top international microbiology journals, indicating a significant recognition of China's scalp care research capabilities [2][10] - Over 11 years, Ziyuan has developed a complete research chain from raw material selection to clinical validation, achieving a closed-loop system that addresses the industry's common issue of disconnect between research and product application [4][18] - The company has established a strong scientific barrier with five patents and five published papers, demonstrating the effectiveness of its products in meeting consumer needs [4][21] Group 2: Market Position and Brand Recognition - Ziyuan has been recognized as the "First Brand of High-end Hair Care in China" by the China Fragrance and Cosmetic Industry Association, breaking the perception that high-end hair care is solely dominated by international brands [5][21] - The brand's success is evidenced by its top rankings on platforms like Douyin and Tmall, reflecting a shift in consumer trust towards domestic high-end products [21][24] Group 3: Innovation in Scalp Care - Ziyuan has redefined the concept of scalp care, emphasizing the importance of scalp health over just hair cleanliness, which has led to a broader consumer awareness [23][29] - The company has pioneered the establishment of standards in scalp microbiome care, moving the industry towards a more scientifically validated approach [6][20] Group 4: Contribution to the Industry - Ziyuan's model serves as a benchmark for domestic brands, demonstrating that scientific rigor and quality can lead to success in the high-end market [18][28] - The publication of the "White Paper on Scalp Microbiome Care" provides a framework for the industry, promoting the development of standards and practices in scalp care [28][29]